{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of CI was not estimable due to low number of participants with events.","groupId":"OG001","lowerLimit":"0.7","upperLimit":"NA","value":"9.6"},{"comment":"Upper limit of CI was not estimable due to low number of participants with events.","groupId":"OG002","lowerLimit":"2.1","upperLimit":"NA","value":"12.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"TTNT defined as the time from the date of brexucabtagene autoleucel infusion to the start of new anti-cancer (including stem cell transplant) therapy prior to documented progression, or death from any cause. KM estimates were used in the outcome measure analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"This substudy was withdrawn; therefore, no participants were enrolled.","id":"OG000","title":"Substudy A (Relapsed/Refractory Waldenstrom Macroglobulinemia): Brexucabtagene Autoleucel"},{"description":"Participants with Relapsed/Refractory Richter Transformation received the following treatment during the study:\n\nLymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3). A single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"OG001","title":"Substudy B (Relapsed/Refractory Richter Transformation): Brexucabtagene Autoleucel"},{"description":"Participants with Relapsed/Refractory Burkitt Lymphoma received the following treatment during the study: Lymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3). A single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"OG002","title":"Substudy C (Relapsed/Refractory Burkitt Lymphoma): Brexucabtagene Autoleucel"},{"description":"Participants with Relapsed/Refractory hairy cell leukemia received the following treatment during the study: Lymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3). A single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"OG003","title":"Substudy D (Relapsed/Refractory Hairy Cell Leukemia): Brexucabtagene Autoleucel"}],"paramType":"MEDIAN","populationDescription":"Participants in substudies B and C, in the Modified Intent-to-Treat Analysis Set were analyzed. Substudy A was withdrawn, therefore no participants were enrolled in it. Hence, data is not available. Substudy D : No participants received next therapy, so no data were reported.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"All Substudies (Substudies A, B, C and D): Time to Next Treatment (TTNT)","type":"SECONDARY","unitOfMeasure":"months"}